Business Description
TScan Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US89854M1018
Total Employee Number:
142Description
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.38 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.96 | |||||
Debt-to-EBITDA | -0.78 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.63 | |||||
Beneish M-Score | -1.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -47.8 | |||||
3-Year EBITDA Growth Rate | 27.3 | |||||
3-Year EPS without NRI Growth Rate | 28.6 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
3-Year Book Growth Rate | -19.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 3.64 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.38 | |||||
9-Day RSI | 39.42 | |||||
14-Day RSI | 42.81 | |||||
3-1 Month Momentum % | -21.47 | |||||
6-1 Month Momentum % | -24.95 | |||||
12-1 Month Momentum % | -53.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.65 | |||||
Quick Ratio | 6.65 | |||||
Cash Ratio | 6.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.9 | |||||
Shareholder Yield % | -1.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1408.74 | |||||
Net Margin % | -1360.61 | |||||
EBITDA Margin % | -1298.65 | |||||
FCF Margin % | -1367.74 | |||||
OCF Margin % | -1335.51 | |||||
ROE % | -82.76 | |||||
ROA % | -46.93 | |||||
ROIC % | -142.48 | |||||
3-Year ROIIC % | 4326.27 | |||||
ROC (Joel Greenblatt) % | -178.18 | |||||
ROCE % | -50.84 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.66 | |||||
PB Ratio | 0.56 | |||||
Price-to-Tangible-Book | 0.56 | |||||
EV-to-EBIT | -0.19 | |||||
EV-to-Forward-EBIT | -0.19 | |||||
EV-to-EBITDA | -0.2 | |||||
EV-to-Revenue | 2.54 | |||||
EV-to-Forward-Revenue | 2.74 | |||||
EV-to-FCF | -0.19 | |||||
Price-to-GF-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 1.95 | |||||
| Price-to-Net-Cash | 2.36 | |||||
Earnings Yield (Greenblatt) % | -526.32 | |||||
FCF Yield % | -212.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TScan Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.136 | ||
| EPS (TTM) ($) | -0.96 | ||
| Beta | 1.9636 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 54.69 | ||
| 14-Day RSI | 42.81 | ||
| 14-Day ATR ($) | 0.099287 | ||
| 20-Day SMA ($) | 0.98475 | ||
| 12-1 Month Momentum % | -53.14 | ||
| 52-Week Range ($) | 0.8251 - 2.57 | ||
| Shares Outstanding (Mil) | 65.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TScan Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TScan Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 26 days | ||
| H.C. Wainwright 4th Annual Cell Therapy | 2026-06-30 11:30 | 0.98 (+1.82%) | ||
| ALLOHA Cohort C Data Call | 2026-06-22 08:30 | 0.92 (+0.97%) | ||
| General meeting for 2026 | 2026-05-20 08:30 | 0.96 (-2.81%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 1.21 (-3.20%) | ||
| the 25(th) Annual Needham Virtual Healthcare Conference | 2026-04-15 15:00 | 1.06 (+2.91%) | ||
| Annual report for 2025 | 2026-03-04 | 1.04 (+4.55%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 1.04 (+4.55%) | ||
| Guggenheim 2(nd) Annual Healthcare Innovation Conference | 2025-11-12 10:00 | 1.22 (+9.91%) |
Show
Entries
TScan Therapeutics Inc Frequently Asked Questions
What is TScan Therapeutics Inc(TCRX)'s stock price today?
The current price of TCRX is $0.90. The 52 week high of TCRX is $2.57 and 52 week low is $0.83.
When is next earnings date of TScan Therapeutics Inc(TCRX)?
The next earnings date of TScan Therapeutics Inc(TCRX) is 2026-08-12 Est..
Does TScan Therapeutics Inc(TCRX) pay dividends? If so, how much?
TScan Therapeutics Inc(TCRX) does not pay dividend.
Guru Commentaries on NAS:TCRX
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies | 2026-06-03 |
Articles on TScan Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers